43.48
10.64%
-5.33
Schlusskurs vom Vortag:
$48.81
Offen:
$45.1
24-Stunden-Volumen:
612.66K
Marktkapitalisierung:
$5.92B
Einnahmen:
$396.59M
Nettoeinkommen (Verlust:
$-528.63M
KGV:
-8.2819
EPS:
-5.25
Netto-Cashflow:
$-595.51M
1W Leistung:
-1.30%
1M Leistung:
-21.99%
6M Leistung:
-7.79%
1J Leistung:
-53.19%
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
502-241-4114
Adresse
6400 Westwind Way, Suite A, Crestwood, KY
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-11-09 | Eingeleitet | Goldman | Buy |
2023-11-02 | Eingeleitet | Mizuho | Neutral |
2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-08-29 | Bestätigt | Citigroup | Buy |
2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
2022-06-17 | Fortgesetzt | Stifel | Buy |
2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
2021-09-10 | Bestätigt | Credit Suisse | Neutral |
2021-09-10 | Bestätigt | Needham | Buy |
2021-09-10 | Bestätigt | Oppenheimer | Outperform |
2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
2021-08-19 | Eingeleitet | Jefferies | Buy |
2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
2021-05-21 | Eingeleitet | UBS | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2020-11-19 | Eingeleitet | Needham | Buy |
2020-09-01 | Eingeleitet | Stifel | Buy |
2020-07-20 | Eingeleitet | ROTH Capital | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Neutral |
2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
2019-11-22 | Eingeleitet | Wedbush | Underperform |
2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire Inc.
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
GlobeNewswire Inc.
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire Inc.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Zacks Investment Research
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
GlobeNewswire Inc.
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Apellis Pharmaceuticals Inc (APLS) Umsatz 2024
APLS meldete einen Umsatz der letzten 12 Monate von 396.59 Millionen US-Dollar für das Quartal zum 2023-12-31, was einem Anstieg von +425.83% im Vergleich zum Vorjahr entspricht.
Apellis Pharmaceuticals Inc (APLS) Nettogewinn 2024
APLS betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -528.63 Millionen US-Dollar, was einem Anstieg von +18.94% im Vergleich zum Vorjahr entspricht.
Apellis Pharmaceuticals Inc (APLS) Free Cashflow 2024
APLS verzeichnete einen Free Cashflow der letzten 12 Monate von -595.51 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Rückgang von -15.57% im Vergleich zum Vorjahr entspricht.
Apellis Pharmaceuticals Inc (APLS) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von APLS für die letzten 12 Monate betrug -4.48 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Wachstum von +26.92% im Vergleich zum Vorjahr entspricht.
Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Deschatelets Pascal | Chief Scientific Officer |
Apr 08 '24 |
Option Exercise |
3.76 |
69,107 |
259,842 |
1,185,090 |
Deschatelets Pascal | Chief Scientific Officer |
Apr 08 '24 |
Sale |
54.17 |
69,107 |
3,743,605 |
1,115,983 |
Sullivan Timothy Eugene | Chief Financial Officer |
Apr 01 '24 |
Option Exercise |
10.03 |
4,000 |
40,120 |
97,338 |
Sullivan Timothy Eugene | Chief Financial Officer |
Apr 01 '24 |
Sale |
58.66 |
4,000 |
234,640 |
93,338 |
Dunlop A. Sinclair | Director |
Mar 19 '24 |
Sale |
57.18 |
18,681 |
1,068,161 |
173,998 |
DeLong Mark Jeffrey | Chief Business & Strat Officer |
Mar 18 '24 |
Sale |
56.90 |
9,913 |
564,050 |
54,693 |
Chopas James George | VP/Chief Accounting Officer |
Mar 15 '24 |
Sale |
56.46 |
184 |
10,389 |
38,883 |
Nicholson Nur | Chief Technical Officer |
Mar 13 '24 |
Sale |
57.56 |
11,220 |
645,838 |
56,287 |
Deschatelets Pascal | Chief Scientific Officer |
Mar 08 '24 |
Option Exercise |
3.67 |
69,107 |
253,623 |
1,185,090 |
Deschatelets Pascal | Chief Scientific Officer |
Mar 08 '24 |
Sale |
62.19 |
69,107 |
4,297,549 |
1,115,983 |
Kapitalisierung:
|
Volumen (24h):